In 30 ALL patients treated with CD19 CAR T cells, a 6-month event-free survival of 67% and overall survival of 78% were achieved, and ongoing remission for up to 2 years was possible without transplantation [45]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.